DecImmune Therapeutics Inks $2.25M
DecImmune Therapeutics has raised $2.25 million in new financing from new investor Broadview Ventures and existing investors Astellas Venture Management and HealthCare Ventures. The company is developing antibody therapeutic to reduce tissue damage and improve ventricular function associated with myocardial infarction.
26 February 2013•3 mins read
